Background and Study Aims: Recurrent dysphagia frequently complicates the palliative treatment of esophageal cancer with self-expanding metal stents. Strategies for repeat interventions and subsequent outcomes have not been adequately reported to date. Patients and Methods: A total of 216 patients underwent placement of a self-expanding metal stent (Ultraflex, n = 75; Flamingo Wallstent, n = 71; Z-stent, n = 70) for malignant dysphagia, and were followed up prospectively. The causes of stent-related recurrent dysphagia, the intervals after first stent placement, and the procedures used for repeat intervention and their outcomes were evaluated. Results: Seventy-four episodes of stent-related recurrent dysphagia occurred in 63 patients (29 %), mainly due to tumor overgrowth (n = 30; median 129 days), stent migration (n = 26; median 92 days) and food bolus obstruction (n = 16; median 80 days). Stent migration occurred more frequently (P = 0.05), whereas tumor overgrowth occurred less frequently (P = 0.05) with Ultraflex stents in comparison with Flamingo Wallstents and Z-stents. Tumor overgrowth was treated in 25 patients mainly by a second stent (n = 19) and was effective in 23 of the 25 patients (92 %). Five patients received no further treatment. Stent migration was treated by placing a second stent (n = 14), repositioning the migrated stent (n = 7), other treatments (n = 3), or no further treatment (n = 2), and treatment was effective in 20 of 24 (83 %) patients. Food bolus obstruction was treated by endoscopic stent clearance in all patients. Repeat intervention for stent-related recurrent dysphagia improved the dysphagia score from a median of 3 to 1 (P < 0.001). The median survival period after repeat treatment was 68 days. Conclusions: Recurrent dysphagia occurs in almost one-third of patients after stent placement. Repeat interventions for stent-related recurrent dysphagia are effective in over 90 % of patients. New innovations in stent design are needed to reduce the risk of stent-related recurrent dysphagia.
References
1
Bollschweiler E, Wolfgarten E, Gutschow C, Holscher A H.
Demographic variations in the rising incidence of esophageal adenocarcinoma in white males.
Cancer.
2001;
92
549-555
2
Botterweck A A, Schouten L J, Volovics A. et al .
Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries.
Int J Epidemiol.
2000;
29
645-654
3
Devesa S S, Blot W J, Fraumeni J F Jr.
Changing patterns in the incidence of esophageal and gastric carcinoma in the United States.
Cancer.
1998;
83
2049-2053
4
Bartelsman J F, Bruno M J, Jensema A J. et al .
Palliation of patients with esophagogastric neoplasms by insertion of a covered expandable modified Gianturco-Z endoprosthesis: experiences in 153 patients.
Gastrointest Endosc.
2000;
51
134-138
5
Christie N A, Buenaventura P O, Fernando H C. et al .
Results of expandable metal stents for malignant esophageal obstruction in 100 patients: short-term and long-term follow-up.
Ann Thorac Surg.
2001;
71
1797-1801; discussion 1801-1802
6
De Palma G D, di Matteo E, Romano G. et al .
Plastic prosthesis versus expandable metal stents for palliation of inoperable esophageal thoracic carcinoma: a controlled prospective study.
Gastrointest Endosc.
1996;
43
478-482
7
Kozarek R A, Raltz S, Brugge W R. et al .
Prospective multicenter trial of esophageal Z-stent placement for malignant dysphagia and tracheoesophageal fistula.
Gastrointest Endosc.
1996;
44
562-567
8
Siersema P D, Hop W C, Dees J. et al .
Coated self-expanding metal stents versus latex prostheses for esophagogastric cancer with special reference to prior radiation and chemotherapy: a controlled, prospective study.
Gastrointest Endosc.
1998;
47
113-120
9
Siersema P D, Hop W C, van Blankenstein M. et al .
A comparison of 3 types of covered metal stents for the palliation of patients with dysphagia caused by esophagogastric carcinoma: a prospective, randomized study.
Gastrointest Endosc.
2001;
54
145-153
10
Knyrim K, Wagner H J, Bethge N. et al .
A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer.
N Engl J Med.
1993;
329
1302-1307
11
De Palma G D, Iovino P, Catanzano C.
Distally migrated esophageal self-expanding metal stents: wait and see or remove?.
Gastrointest Endosc.
2001;
53
96-98
13
Wang M Q, Sze D Y, Wang Z P. et al .
Delayed complications after esophageal stent placement for treatment of malignant esophageal obstructions and esophagorespiratory fistulas.
J Vasc Interv Radiol.
2001;
12
465-474
14
Ogilvie A L, Dronfield M W, Ferguson R, Atkinson M.
Palliative intubation of oesophagogastric neoplasms at fibre-optic endoscopy.
Gut.
1982;
23
1060-1067
15
Mayoral W, Fleischer D, Salcedo J. et al .
Nonmalignant obstruction is a common problem with metal stents in the treatment of esophageal cancer.
Gastrointest Endosc.
2000;
51
556-559
16
Harbord M, Dawes R F, Barr H. et al .
Palliation of patients with dysphagia due to advanced esophageal cancer by endoscopic injection of cisplatin/epinephrine injectable gel.
Gastrointest Endosc.
2002;
56
644-651
17
Won J H, Lee J D, Wang H J. et al .
Self-expandable covered metallic esophageal stent impregnated with beta-emitting radionuclide: an experimental study in canine esophagus.
Int J Radiat Oncol Biol Phys.
2002;
53
1005-1013
18
Di Fiore F, Lecleire S, Antonietti M. et al .
Spontaneous passage of a dislocated esophageal metal stent: report of two cases.
Endoscopy.
2003;
35
223-225
20
Berkelhammer C, Roberts J, Steinecker G.
Repositioning a migrated esophageal stent using a retroflexed endoscope: a note of caution.
Gastrointest Endosc.
1996;
44
632-634
21
Fry S W, Fleischer D E.
Management of a refractory benign esophageal stricture with a new biodegradable stent.
Gastrointest Endosc.
1997;
45
179-182
22
Ell C, May A.
Self-expanding metal stents for palliation of stenosing tumors of the esophagus and cardia: a critical review.
Endoscopy.
1997;
29
392-398
23
Siersema P D, Hop W C, van Blankenstein M, Dees J.
A new design metal stent (Flamingo stent) for palliation of malignant dysphagia: a prospective study. The Rotterdam Esophageal Tumor Study Group.
Gastrointest Endosc.
2000;
51
139-145